Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

NEWS Press Release Media Report

Year:

Select

Press Release

14 September 2022

Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line（1L）treatment for NSCLC at ESMO 2022 the 2-year follow-up results confirmed that both non-squamous and squamous NSCLC can benefit from KN046 as first-line treatment in the long-term
14 September 2022

Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ) chemo-free regimen showed excellent efficacy in 1st line HER2-positive gastric cancer
09 August 2022

First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer We believe that KN046 combined with the anti-angiogenic drug Axitinib also has well-acceptable safety and anti-tumor potential, bringing a new first-line'chemotherapy-free' treatment strateg...
01 August 2022

New Data from Alphamab Oncology’s KN046 and KN026 to be Presented at the ESMO Congress 2022 data from three clinical studies of KN046 (PD-L1/CTLA4 bispecific antibody) and KN026 (anti-HER2 bispecific antibody) will be presented in four e-Posters at the ESMO Congress 2022
14 June 2022

Alphamab Oncology Announced First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052 to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN052, and to determine the recommended dose for further development.
06 June 2022

Poster Highlighting Phase II Clinical Study of KN026 for HER2-expressing Advanced GC/GEJ Presented at 2022 ASCO A phase II study evaluating KN026 monotherapy in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers
06 June 2022

Research Updates on KN046 Presented at 2022 ASCO four clinical studies of KN046 presented as a poster or published online at the 2022 ASCO.
27 May 2022

First Patient Dosed in Phase II Clinical Study of Alphamab Oncology’s KN026 Combined with Pfizer’s Ibrance® (palbociclib) We hope that KN026 combined with a CDK4/6 inhibitor and estrogen receptor antagonist could bring better treatment options to patients.
28 April 2022

Posters to Highlight Clinical Studies of KN046 and KN026 will be Presented at 2022 ASCO posters will be presented at the 2022 American Society of Clinical Oncology Annual Meeting to be held from June 3th to June 7th
27 April 2022

Envafolimab Included in Three Updated 2022 CSCO Guidelines Envafolimab was included for the first time into 3 CSCO guidelines, and received recommendation and attention by experts during the meeting